Rifampicin
Rifampicin (rifampin; RIF) is a rifamycin antimicrobial used as a core component of combination therapy for tuberculosis, commonly alongside isoniazid, pyrazinamide, and—when indicated—ethambutol or other agents.
Rifampicin (rifampin; RIF) is a rifamycin antimicrobial used as a core component of combination therapy for tuberculosis, commonly alongside isoniazid, pyrazinamide, and—when indicated—ethambutol or other agents. It is used in the management of severe and disseminated disease, including tuberculous meningitis, and remains clinically important in patients with concurrent conditions such as HIV or active hepatitis B. Its pharmacokinetics and drug–drug interactions are major considerations in treatment, including interactions involving antiretroviral therapy, metformin, itraconazole, and pathways related to cytochrome P450 3A4 (CYP3A4).
Current research seeks to improve rifampicin exposure, tolerability, and delivery to infected tissues and cells. Investigational approaches include macrophage-directed nanoparticles, nanohydrogels, liposomes, exosomal vesicles, and fixed-dose 3D-printed tablets designed to address intracellular tuberculosis treatment or formulation-related bioavailability challenges. Rifampicin is also being evaluated in physiologically based pharmacokinetic modeling using absolute protein-abundance data and in exploratory antibacterial applications involving Klebsiella pneumoniae and other resistant bacteria; these studies remain distinct from its established role in tuberculosis therapy.
- Rifampicin and long-acting cabotegravir-rilpivirine: Therapeutic drug monitoring-guided management of a major drug-drug interaction-A case report. PMID 43035988
Where the papers sit
9 papers from the last 6 months study rifampicin directly
Study type 1 clinical trial · 2 observational · 3 human data · 3 preclinical
Themes one subject
Those 9 are all about one subject.
-
Antimicrobial Pharmacology and Delivery
Antitubercular treatment is moving toward more targeted delivery and individualized dosing. Macrophage-directed nanoparticles, nanohydrogels, liposomes and fixed-dose 3D-printed tablets aim to improve rifampicin exposure and site-specific efficacy. Pharmacokinetic studies emphasize drug interactions, including metformin effects, and more accurate PBPK models based on absolute protein abundances. Clinical management remains central, while broader antibacterial applications and unresolved safety and effectiveness questions keep the field exploratory.
Papers
The 9 papers from the last 6 months that study rifampicin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Antimicrobial Pharmacology and Delivery (9)
- PMID 42156860
- Multidisciplinary management of disseminated tuberculosis with tuberculous meningitis and active hepatitis B in a critically ill pregnant woman in the third trimester: a case report. Infectious diseases of poverty · 9 Nov 2026 PMID 43004400
- Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment. Molecular pharmaceutics · 2 Nov 2026 PMID 42969738
- Single-step Sintered 3D-printed Fixed-dose Combined Bilayer Tablets for Compartmentalized Delivery of First-line Anti-tubercular Drugs. The AAPS journal · 9 Sept 2026 PMID 42711607
- Transitioning from Transcriptomics to Proteomics: Enhancing Mechanistic Accuracy in PBPK Modeling via Absolute Protein Abundances. CPT: pharmacometrics & systems pharmacology · 20 Aug 2026 PMID 42618963
- Towards macrophage-oriented Antituberculosis therapy: nanohydrogel and liposomal delivery of rifampicin-berberine Co-nanocrystals for enhanced intracellular Antituberculosis activity. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 18 Aug 2026 PMID 42612927
- The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial agents and chemotherapy · 6 Aug 2026 PMID 42560062
- Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467063
- ADMCs-derived exosomal vesicles encapsulated with rifampicin to attenuate Klebsiella pneumonia-induced pediatric lung inflammation: In-vitro and In vivo studies. Microbial pathogenesis · 10 Jun 2026 PMID 42269980
By study type
Clinical trials (1)
- The effect of metformin on the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide in adults with tuberculosis. Antimicrobial agents and chemotherapy · 6 Aug 2026 PMID 42560062
Observational studies and case reports (2)
- Rifampicin and long-acting cabotegravir-rilpivirine: Therapeutic drug monitoring-guided management of a major drug-drug interaction-A case report. British journal of clinical pharmacology · 16 Nov 2026 PMID 43035988
- Multidisciplinary management of disseminated tuberculosis with tuberculous meningitis and active hepatitis B in a critically ill pregnant woman in the third trimester: a case report. Infectious diseases of poverty · 9 Nov 2026 PMID 43004400
Human data, design not indexed (3)
- Enhancing TB Therapy with Precision: Immunomodulatory Nanoparticles Co-Delivering Rifampicin and Vitamin D3 for Macrophage-Targeted Treatment. Molecular pharmaceutics · 2 Nov 2026 PMID 42969738
- Towards macrophage-oriented Antituberculosis therapy: nanohydrogel and liposomal delivery of rifampicin-berberine Co-nanocrystals for enhanced intracellular Antituberculosis activity. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 18 Aug 2026 PMID 42612927
- Population pharmacokinetics of ritonavir-boosted atazanavir in subsequent-line treatment in African children with HIV. Antimicrobial agents and chemotherapy · 17 Jul 2026 PMID 42467063
Preclinical: animal, cell and lab studies (3)
- Single-step Sintered 3D-printed Fixed-dose Combined Bilayer Tablets for Compartmentalized Delivery of First-line Anti-tubercular Drugs. The AAPS journal · 9 Sept 2026 PMID 42711607
- Transitioning from Transcriptomics to Proteomics: Enhancing Mechanistic Accuracy in PBPK Modeling via Absolute Protein Abundances. CPT: pharmacometrics & systems pharmacology · 20 Aug 2026 PMID 42618963
- ADMCs-derived exosomal vesicles encapsulated with rifampicin to attenuate Klebsiella pneumonia-induced pediatric lung inflammation: In-vitro and In vivo studies. Microbial pathogenesis · 10 Jun 2026 PMID 42269980
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-11-12. Drafted by language models from published abstracts; not medical advice.